PeriCor Therapeutics, Inc. Company Profile
PeriCor Therapeutics, Inc. is a privately-held specialty biopharmaceutical company focused on the development and commercialization of a new class of medicines, adenosine regulating agents, to improve treatment and patient outcomes in acute-care settings of ischemia/reperfusion injury and heart failure. In August 2007, PeriCor granted worldwide development and commercialization rights for its first generation ARA, acadesine, to Schering-Plough Corporation under a licensing agreement. Last month, Schering-Plough announced the initiation of a Phase III pivotal trial of acadesine, an investigational drug, to reduce serious adverse cardiovascular outcomes associated with CABG surgery.
Drugs and Medications
PeriCor Therapeutics, Inc. is a privately-held specialty biopharmaceutical company focused on the development and commercialization of a new class of medicines, adenosine regulating agents, to improve...
More Information about "PeriCor Therapeutics, Inc." on BioPortfolio
We have published hundreds of PeriCor Therapeutics, Inc. news stories on BioPortfolio along with dozens of PeriCor Therapeutics, Inc. Clinical Trials and PubMed Articles about PeriCor Therapeutics, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of PeriCor Therapeutics, Inc. Companies in our database. You can also find out about relevant PeriCor Therapeutics, Inc. Drugs and Medications on this site too.